A Phase 2 interventional study of Placebo and PF-06649751 low dose (1 mg QD) in Parkinson Disease, sponsored by Pfizer. Terminated at 57 sites in 6 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-11-23.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing tavapadon in Parkinson Disease — none open to participants now, none under way, none of them phase 3. tavapadon · Parkinson Disease.
Among the 11 studies testing tavapadon in Parkinson Disease, this one is the 5th largest by enrollment, is one of 2 that started in 2016, is one of 2 in phase 2, and was the 3rd registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.
Browse Parkinson Disease studies →None of the 11 studies testing tavapadon in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →
tavapadon: first FDA approval 2026 (JUVMO). What it is approved for, and how studies give it, is on its page →
Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 2 started in 2016.
This study's enrollment of 108 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.
Median enrollment 57 across the 11 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 3 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
15 studies in Parkinson Disease by Pfizer: none open now, none under way, none of them phase 3. Of 15 finished, 7 (47%) have results posted.
Among the 15 studies in Parkinson Disease by Pfizer, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2016, is one of 4 in phase 2, and was the 13th registered.
Pfizer’s Parkinson Disease studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing tavapadon in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 15 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
The study has a randomized, double-blind, placebo-controlled parallel group design. Approximately 198 subjects will be randomized to 5 treatment groups. Each subject will participate in the study for approximately 23 weeks including a 30 day screening period, 15 week double blind treatment period, and an approximately 28 day follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo
Drug: Placebo
PF-06649751 low dose level (1 mg QD)
Drug: PF-06649751 low dose (1 mg QD)
PF-06649751 lower middle dose 1 (3 mg QD)
Drug: PF-06649751 middle dose 1 (3 mg QD)
PF-06649751 higher middle dose 2 (7 mg QD)
Drug: PF-06649751 middle dose 2 (7 mg QD)
PF-06649751 high dose (15 mg QD)
Drug: PF-06649751 high dose (15 mg QD)
Placebo
PF-06649751 low dose (1 mg QD)
PF-06649751 lower middle dose 1 (3 mg QD)
PF-06649751higher middle dose 2 (7 mg QD)
PF-06649751 high dose (15 mg QD)
Change From Baseline in Daily OFF Time at Week 10
A paper Hauser diary was utilized to record motor state for half-hour intervals. Participants completed the diary by answering whether they had been OFF for 3 consecutive days in the week prior to each visit (except Day 28 visit), including 3 consecutive days during the week prior to Day 0 (Randomization). The daily OFF time was calculated as the average of the 3 consecutive daily OFF hours from the Hauser diary at each visit.
Time frame: Week 10; Baseline was defined as the average daily OFF time (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit day 0).
Change From Baseline in Daily OFF Time
A paper Hauser diary was utilized to record motor state for half hour intervals. Participants completed the diary by answering whether they had been OFF for 3 consecutive days in the week prior to each visit (except Day 28 visit), including 3 consecutive days during the week prior to Day 0 (Randomization). The daily OFF time was calculated as the average of the 3 consecutive daily OFF hours from the Hauser diary at each visit. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.
Time frame: Weeks 3, 5, 10 and 15; Baseline was defined as the average daily OFF time (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit day 0).
Change From Baseline in Daily ON Time With Troublesome Dyskinesia
A paper Hauser diary was utilized to record motor state for half hour intervals. The participants answered the Hauser diary on whether they had been ON with troublesome dyskinesia. A diary day started with the interval 24:00-0:30 through 23:30-24:00 on each chronological day for 3 consecutive days. On the days recording the home diary, participants made an entry every 30 minutes during their normal waking time and upon awakening from time asleep. The daily ON hours was calculated as the average of the 3 consecutive daily ON hours from the Hauser diary at each visit. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.
Time frame: Weeks 3, 5, 10 and 15; Baseline was defined as the average daily ON time with Troublesome Dyskinesia (using 3 Hauser patient diary Days) prior to Day -1 (study derived day and equalled to nominal visit Day 0).
Change From Baseline in Daily ON Time Without Troublesome Dyskinesia
A paper Hauser diary was utilized to record motor state for half hour intervals. The participants answered the Hauser diary on whether they had been ON without troublesome dyskinesia. A diary day started with the interval 24:00-0:30 through 23:30-24:00 on each chronological day for 3 consecutive days. On the days recording the home diary, participants made an entry every 30 minutes during their normal waking time and upon awakening from time asleep. The daily ON hours was calculated as the average of the 3 consecutive daily ON hours from the Hauser diary at each visit. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.
Time frame: Weeks 3, 5, 10 and 15; Baseline was defined as the average daily ON time without Troublesome Dyskinesia (using 3 Hauser patient diary days) prior to Day -1 (study derived day and equalled to nominal visit Day 0)
Change From Baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III
MDS-UPDRS Part III assessed the motor signs of Parkinson's disease and was administered by the investigator. It was comprised of 33 sub-scores based on 18 items, several with right, left or other body distribution scores. Each question was anchored with 5 responses that were linked to commonly accepted clinical terms: 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. If more than 7 of the Part III items were missing, the score for that time point was missing, otherwise MDS-UPDRS Part III score was imputed as sum of the non-missing items\*(total number of items)/ (number of items non-missing). The MDS-UPDRS Part III total score range is 0-132. Higher score indicated more severe motor signs of Parkinson's disease. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.
Time frame: Weeks 1, 2, 3, 4, 5, 10 and 15; Baseline was defined as the Day -1 (study derived day and equalled to nominal visit Day 0) measurement
Change From Baseline in Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, IV, and Total Score
Each question of Part I,II or IV with 5 responses was linked to the same clinical terms as Part III.The score was missing if more than 7 items were missing for a time point; otherwise Part I,II or IV score was imputed as sum of non-missing items\*(total number of items)/(number of items non-missing).•PartI (Non-Motor Aspects of Experiences of Daily Living) assessed non-motor experiences of daily living using 13questions(Range:0-52).•PartII(Motor Aspects of Experiences of Daily Living) assessed motor experiences of daily living using 13questions(Range:0-52).•PartIV(Motor Complications) assessed motor complications,dyskinesias, and motor fluctuations using historical and objective information with 6questions(Range:0-24).•MDS-UPDRS Total Score:the sum of Parts I,II,III,and IV(Range:0-260).Higher score indicated more severe motor signs of Parkinson's disease.Week15's results were interpreted cautiously given almost half participants were not available for the analysis as compared to Week10
Time frame: Weeks 5, 10 and 15; Baseline was defined as the Day -1 (study derived day and equalled to nominal visit Day 0) measurement
Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality
The safety laboratory tests including Hematology, Clinical Chemistry and Urinalysis were performed. Determination if there were any laboratory data abnormalities of potential clinical concern was based on Pfizer Data Standards. Incidence of laboratory test abnormalities (without regard to baseline abnormality) was summarized within each treatment group.
Time frame: Baseline (Day 0) to Week 17
Number of Participants With Vital Sign Results Meeting the Criteria for Categorical Summarization
Vital Signs including blood pressure and pulse rate were measured. Vital signs were collected first while the participant was in the supine position and then in the standing position.
Time frame: Baseline (Day 0) to Week 17
Number of Participants With Electrocardiogram (ECG) Results Meeting the Criteria for Categorical Summarization
The average of the triplicate readings of ECG data was collected at each assessment time. Number of participants with ECG results meeting the criteria for categorical summarization for time from the beginning of the P wave until the beginning of the QRS complex (PR Interval), time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS Duration), time between the start of the Q wave and the end of the T wave in the heart's electrical cycle (QT Interval) and corrected QT (Fridericia correction) (QTcF Interval) were presented.
Time frame: Baseline (Day 0) to Week 17
Number of Participants With Suicidal Ideation Assessed Using the Columbia Suicide Severity Rating Scale (C-SSRS) at Post-baseline Visits
The Columbia Suicide Severity Rating Scale (C-SSRS) was an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS responses were mapped to the C-CASA. There were 3 key endpoints for suicidality data analysis and evaluation: * Suicidal Behavior: A participant was said to have suicidal behavior if the participant had experienced completed suicide / suicide attempt / reparatory acts toward imminent suicidal behavior. * Suicidal Ideation: Any observed suicidal ideation mapped to a single C-CASA category. * Suicidal Behavior or Ideation (participants with new onset suicidality): A participant was considered to have a new onset of suicidality if the participant reported no ideation and no behavior at the baseline assessment and reported any behavior or ideation post-baseline. Data observed at screening was not considered in the definition of worsening.
Time frame: Days 0 (Baseline), 7, 14, 21, 28, 35, 70, 77, 84, 91, 105 and 119
Change From Baseline in Total Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease - Rating Scale (QUIP-RS)
The QUIP-RS was a brief, patient reported outcome measure designed to assess the severity of symptoms of Impulsive-Compulsive Disorders (ICDs) and related behaviors reported to occur in Parkinson's disease. The QUIP-RS assessed 7 disorders (Gambling, Sex, Buying, Eating, Hobbyism-punding \[performing tasks and repeating activities\] and Taking medications). If more than 5 items were missing, the total QUIP-RS score was set as missing; otherwise, the total QUIP-RS score was imputed as follows: sum of the non-missing item scores \* (total number of items) / (number of items non-missing). The higher score indicated a greater level of the ICD. The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112.
Time frame: Baseline (Day 0) and Weeks 5, 10 and 15
Total Physician Withdrawal Checklist (PWC-20) on Days 105 and 119, and Change From Day 105 to Day 119
The PWC-20 is a physician completed, 20 item reliable and sensitive instrument for the assessment of discontinuation symptoms. The PWC-20 was collected after the completion of study treatment and also at the first visit of follow-up. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. If more than 5 items were missing, the total PWC-20 score was missing; otherwise, the total PWC-20 score was imputed as follows: sum of the non-missing items \* (total number of items) / (number of items non-missing). The higher score indicated more frequent/severe symptoms.
Time frame: Days 105 and 119
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Discontinuation Due to AEs and Deaths
An AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event did not need necessarily to have a causal relationship with the treatment or usage. An SAE was any untoward medical occurrence at any dose that: * Resulted in death; * Was life threatening (immediate risk of death); * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); * Resulted in congenital anomaly/birth defect.
Time frame: Day 1 to follow-up (Week 19 visit)
| Milestone | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| Started | 23 | 13 | 15 | 13 | 44 |
| Completed | 15 | 1 | 1 | 3 | 24 |
| Not completed | 8 | 12 | 14 | 10 | 20 |
| Withdrew: Medication error without associated aes | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 5 | 9 | 10 | 6 | 5 |
| Withdrew: Adverse event | 3 | 1 | 3 | 2 | 9 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 2 | 4 |
A paper Hauser diary was utilized to record motor state for half-hour intervals. Participants completed the diary by answering whether they had been OFF for 3 consecutive days in the week prior to each visit (except Day 28 visit), including 3 consecutive days during the week prior to Day 0 (Randomization). The daily OFF time was calculated as the average of the 3 consecutive daily OFF hours from the Hauser diary at each visit.
| Hours | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| Change From Baseline in Daily OFF Time at Week 10 | -0.969 ± 0.4092 | -1.173 ± 0.3482 | -1.316 ± 0.3289 | -1.480 ± 0.3460 | -1.663 ± 0.4297 |
A paper Hauser diary was utilized to record motor state for half hour intervals. Participants completed the diary by answering whether they had been OFF for 3 consecutive days in the week prior to each visit (except Day 28 visit), including 3 consecutive days during the week prior to Day 0 (Randomization). The daily OFF time was calculated as the average of the 3 consecutive daily OFF hours from the Hauser diary at each visit. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.
| Hours | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| Change at Week 3 | -0.67 ± 0.620 | -0.82 ± 1.237 | -0.55 ± 1.091 | -1.82 ± 1.182 | -1.01 ± 0.464 |
| Change at Week 5 | -0.63 ± 0.490 | -2.04 ± 1.054 | -2.23 ± 0.964 | -1.41 ± 0.937 | -1.24 ± 0.392 |
| Change at Week 10 | -0.99 ± 0.628 | -0.60 ± 1.423 | -1.00 ± 1.508 | -2.07 ± 1.187 | -1.63 ± 0.502 |
| Change at Week 15 | 1.05 ± 1.063 | -0.67 ± 2.960 | -2.75 ± 2.936 | -1.09 ± 1.687 | -2.47 ± 0.793 |
A paper Hauser diary was utilized to record motor state for half hour intervals. The participants answered the Hauser diary on whether they had been ON with troublesome dyskinesia. A diary day started with the interval 24:00-0:30 through 23:30-24:00 on each chronological day for 3 consecutive days. On the days recording the home diary, participants made an entry every 30 minutes during their normal waking time and upon awakening from time asleep. The daily ON hours was calculated as the average of the 3 consecutive daily ON hours from the Hauser diary at each visit. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.
| Hours | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| Change at Week 3 | 0.17 ± 0.236 | 0.07 ± 0.467 | 0.19 ± 0.417 | 0.01 ± 0.464 | 0.23 ± 0.179 |
| Change at Week 5 | 0.23 ± 0.198 | -0.21 ± 0.415 | -0.02 ± 0.388 | 0.45 ± 0.363 | 0.03 ± 0.162 |
| Change at Week 10 | 0.13 ± 0.191 | 0.24 ± 0.464 | 0.32 ± 0.529 | -0.39 ± 0.389 | 0.13 ± 0.167 |
| Change at Week 15 | 0.01 ± 0.642 | -0.43 ± 1.349 | -0.29 ± 1.263 | 0.54 ± 1.071 | -0.21 ± 0.463 |
A paper Hauser diary was utilized to record motor state for half hour intervals. The participants answered the Hauser diary on whether they had been ON without troublesome dyskinesia. A diary day started with the interval 24:00-0:30 through 23:30-24:00 on each chronological day for 3 consecutive days. On the days recording the home diary, participants made an entry every 30 minutes during their normal waking time and upon awakening from time asleep. The daily ON hours was calculated as the average of the 3 consecutive daily ON hours from the Hauser diary at each visit. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.
| Hours | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| Change at Week 3 | 0.61 ± 0.577 | 1.74 ± 1.173 | -0.49 ± 1.047 | 1.93 ± 1.128 | 0.77 ± 0.443 |
| Change at Week 5 | 0.02 ± 0.548 | 2.39 ± 1.150 | 1.31 ± 1.058 | 1.12 ± 1.029 | 1.31 ± 0.436 |
| Change at Week 10 | 0.61 ± 0.618 | 0.92 ± 1.413 | 0.45 ± 1.598 | 2.64 ± 1.194 | 1.65 ± 0.508 |
| Change at Week 15 | -0.81 ± 1.099 | 0.37 ± 2.999 | -4.48 ± 3.192 | 0.94 ± 1.781 | 1.50 ± 0.825 |
MDS-UPDRS Part III assessed the motor signs of Parkinson's disease and was administered by the investigator. It was comprised of 33 sub-scores based on 18 items, several with right, left or other body distribution scores. Each question was anchored with 5 responses that were linked to commonly accepted clinical terms: 0 = normal, 1 = slight, 2 = mild, 3 = moderate, and 4 = severe. If more than 7 of the Part III items were missing, the score for that time point was missing, otherwise MDS-UPDRS Part III score was imputed as sum of the non-missing items\*(total number of items)/ (number of items non-missing). The MDS-UPDRS Part III total score range is 0-132. Higher score indicated more severe motor signs of Parkinson's disease. Results at Week 15 should be interpreted with caution given almost half the participants were not available for this analysis at Week 15 as compared to Week 10 and the complicated nature of protocol changes that impacted the study design after Week 10.
| units on a scale | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| Change at Week 1 | -3.90 ± 2.054 | -4.44 ± 3.965 | -4.61 ± 3.593 | -1.90 ± 3.594 | -3.22 ± 1.524 |
| Change at Week 2 | -0.95 ± 2.078 | -15.78 ± 6.252 | — | 0.56 ± 6.129 | -3.70 ± 1.584 |
| Change at Week 3 | -3.80 ± 2.848 | -12.39 ± 8.240 | — | — | -3.06 ± 2.069 |
| Change at Week 4 | -6.28 ± 2.182 | -0.84 ± 3.940 | -2.48 ± 3.572 | -2.91 ± 3.575 | -6.05 ± 1.574 |
| Change at Week 5 | -5.12 ± 2.386 | -6.14 ± 4.414 | 3.10 ± 4.347 | -1.22 ± 3.935 | -4.86 ± 1.765 |
| Change at Week 10 | -5.09 ± 1.967 | -2.21 ± 3.902 | 5.77 ± 5.365 | -2.36 ± 3.607 | -9.32 ± 1.526 |
| Change at Week 15 | -0.18 ± 3.170 | 7.72 ± 8.660 | 2.09 ± 9.495 | -5.44 ± 5.364 | -1.84 ± 2.519 |
Each question of Part I,II or IV with 5 responses was linked to the same clinical terms as Part III.The score was missing if more than 7 items were missing for a time point; otherwise Part I,II or IV score was imputed as sum of non-missing items\*(total number of items)/(number of items non-missing).•PartI (Non-Motor Aspects of Experiences of Daily Living) assessed non-motor experiences of daily living using 13questions(Range:0-52).•PartII(Motor Aspects of Experiences of Daily Living) assessed motor experiences of daily living using 13questions(Range:0-52).•PartIV(Motor Complications) assessed motor complications,dyskinesias, and motor fluctuations using historical and objective information with 6questions(Range:0-24).•MDS-UPDRS Total Score:the sum of Parts I,II,III,and IV(Range:0-260).Higher score indicated more severe motor signs of Parkinson's disease.Week15's results were interpreted cautiously given almost half participants were not available for the analysis as compared to Week10
| units on a scale | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| Change at Week 5 (Part I Score) | -0.75 ± 5.508 | -0.83 ± 1.941 | 0.67 ± 4.885 | 2.00 ± 4.408 | 1.12 ± 4.879 |
| Change at Week 10 (Part I Score) | -0.69 ± 4.557 | -0.80 ± 2.168 | -1.00 ± 2.828 | 0.00 ± 2.449 | 0.17 ± 4.086 |
| Change at Week 15 (Part I Score) | -2.86 ± 6.176 | 2.00 ± NA | 6.00 ± NA | -1.00 ± 1.732 | 1.00 ± 5.745 |
| Change at Week 5 (Part II Score) | 0.06 ± 5.836 | -1.83 ± 2.639 | 3.00 ± 4.940 | -0.03 ± 3.083 | -0.24 ± 4.068 |
| Change at Week 10 (Part II Score) | -0.35 ± 5.267 | -1.00 ± 1.225 | 5.00 ± 1.414 | 0.13 ± 2.428 | -0.43 ± 4.240 |
| Change at Week 15 (Part II Score) | -1.38 ± 4.779 | 2.00 ± NA | 8.00 ± NA | -2.42 ± 5.270 | 1.47 ± 5.986 |
| Change at Week 5 (Part IV Score) | -1.50 ± 2.895 | -0.83 ± 2.401 | -0.50 ± 4.848 | 0.25 ± 2.053 | -0.65 ± 2.806 |
| Change at Week 10 (Part IV Score) | -2.00 ± 2.318 | 0.80 ± 1.304 | -3.00 ± 5.657 | 0.00 ± 1.789 | -1.13 ± 3.530 |
| Change at Week 15 (Part IV Score) | -2.75 ± 2.493 | -2.00 ± NA | -7.00 ± NA | -1.33 ± 2.082 | -1.27 ± 2.404 |
| Change at Week 5 (Total Score) | -8.88 ± 12.832 | -10.00 ± 7.616 | 5.33 ± 16.860 | 2.34 ± 12.010 | -4.21 ± 18.216 |
| Change at Week 10 (Total Score) | -8.75 ± 10.951 | -3.60 ± 8.649 | 6.50 ± 7.778 | 0.13 ± 10.569 | -11.40 ± 18.448 |
| Change at Week 15 (Total Score) | -7.86 ± 12.456 | 0.00 ± NA | 13.00 ± NA | -9.08 ± 13.135 | 0.73 ± 17.260 |
The safety laboratory tests including Hematology, Clinical Chemistry and Urinalysis were performed. Determination if there were any laboratory data abnormalities of potential clinical concern was based on Pfizer Data Standards. Incidence of laboratory test abnormalities (without regard to baseline abnormality) was summarized within each treatment group.
| Participants | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality | 19 | 4 | 9 | 7 | 25 |
Vital Signs including blood pressure and pulse rate were measured. Vital signs were collected first while the participant was in the supine position and then in the standing position.
| Participants | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| <90 mmHg (Supine Systolic Blood Pressure [SBP]) | 1 | 1 | 2 | 0 | 3 |
| Max-Increase from Baseline >= 30 mmHg (Supine SBP) | 4 | 1 | 2 | 1 | 3 |
| Max-Decrease from Baseline >= 30 mmHg (Supine SBP) | 4 | 1 | 2 | 2 | 11 |
| <90 mmHg (Standing SBP) | 4 | 1 | 3 | 2 | 7 |
| Max-Increase from Baseline >=30mmHg (Standing SBP) | 4 | 0 | 3 | 1 | 3 |
| Max-Decrease from Baseline >=30mmHg (Standing SBP) | 3 | 0 | 3 | 2 | 12 |
| <50 mmHg (Supine Diastolic Blood Pressure [DBP]) | 0 | 0 | 0 | 1 | 1 |
| Max-Increase from Baseline >=20 mmHg (Supine DBP) | 1 | 0 | 0 | 1 | 3 |
| Max-Decrease from Baseline >=20 mmHg (Supine DBP) | 1 | 0 | 2 | 1 | 13 |
| <50 mmHg (Standing DBP) | 2 | 0 | 1 | 2 | 1 |
| Max-Increase from Baseline >=20mmHg (Standing DBP) | 3 | 0 | 2 | 0 | 1 |
| Max-Decrease from Baseline >=20mmHg (Standing DBP) | 5 | 2 | 3 | 2 | 17 |
| <40 beats per minute (bpm) (Supine Pulse Rate) | 0 | 0 | 0 | 0 | 0 |
| >120 bpm (Supine Pulse Rate) | 0 | 0 | 0 | 0 | 0 |
| <40 bpm (Standing Pulse Rate) | 0 | 0 | 0 | 0 | 0 |
| >140 bpm (Standing Pulse Rate) | 0 | 0 | 0 | 0 | 0 |
The average of the triplicate readings of ECG data was collected at each assessment time. Number of participants with ECG results meeting the criteria for categorical summarization for time from the beginning of the P wave until the beginning of the QRS complex (PR Interval), time from ECG Q wave to the end of the S wave corresponding to ventricle depolarization (QRS Duration), time between the start of the Q wave and the end of the T wave in the heart's electrical cycle (QT Interval) and corrected QT (Fridericia correction) (QTcF Interval) were presented.
| Participants | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| >=300 msec (PR Interval) | 1 | 0 | 0 | 0 | 0 |
| Max-Increase From Baseline(%)>=25/50%(PR Interval) | 0 | 0 | 0 | 0 | 0 |
| >=140 msec (QRS Duration) | 0 | 0 | 0 | 0 | 0 |
| Max-Increase From Baseline(%)>=50% (QRS Duration) | 0 | 0 | 0 | 0 | 0 |
| >=500 msec (QT Interval) | 1 | 0 | 0 | 0 | 0 |
| 450 - <480 msec (QTcF Interval) | 2 | 0 | 0 | 0 | 1 |
| 480 - <500 msec (QTcF Interval) | 0 | 0 | 0 | 0 | 0 |
| >=500 msec (QTcF Interval) | 0 | 0 | 0 | 0 | 0 |
| Max-Increase From Baseline 30-<60 (QTcF Interval) | 1 | 0 | 0 | 0 | 1 |
| Max-Increase From Baseline >=60 (QTcF Interval) | 0 | 0 | 0 | 0 | 0 |
The Columbia Suicide Severity Rating Scale (C-SSRS) was an interview based rating scale to systematically assess suicidal ideation and suicidal behavior. C-SSRS responses were mapped to the C-CASA. There were 3 key endpoints for suicidality data analysis and evaluation: * Suicidal Behavior: A participant was said to have suicidal behavior if the participant had experienced completed suicide / suicide attempt / reparatory acts toward imminent suicidal behavior. * Suicidal Ideation: Any observed suicidal ideation mapped to a single C-CASA category. * Suicidal Behavior or Ideation (participants with new onset suicidality): A participant was considered to have a new onset of suicidality if the participant reported no ideation and no behavior at the baseline assessment and reported any behavior or ideation post-baseline. Data observed at screening was not considered in the definition of worsening.
| Participants | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| Baseline | 1 | 0 | 1 | 0 | 0 |
| Day 7 | 0 | 0 | 0 | 0 | 0 |
| Day 14 | 0 | 0 | 0 | 0 | 1 |
| Day 21 | 0 | 0 | 0 | 0 | 2 |
| Day 28 | 0 | 0 | 0 | 0 | 0 |
| Day 35 | 0 | 0 | 0 | 0 | 1 |
| Day 70 | 0 | 0 | 0 | 0 | 0 |
| Day 77 | 0 | — | — | — | 0 |
| Day 84 | 0 | — | — | — | 0 |
| Day 91 | 0 | — | — | — | 0 |
| Day 105 | 0 | 0 | 0 | 1 | 0 |
| Day 119 | 0 | 0 | — | 0 | 0 |
The QUIP-RS was a brief, patient reported outcome measure designed to assess the severity of symptoms of Impulsive-Compulsive Disorders (ICDs) and related behaviors reported to occur in Parkinson's disease. The QUIP-RS assessed 7 disorders (Gambling, Sex, Buying, Eating, Hobbyism-punding \[performing tasks and repeating activities\] and Taking medications). If more than 5 items were missing, the total QUIP-RS score was set as missing; otherwise, the total QUIP-RS score was imputed as follows: sum of the non-missing item scores \* (total number of items) / (number of items non-missing). The higher score indicated a greater level of the ICD. The total QUIP-RS score for all ICDs and related disorders combined ranges from 0 to 112.
| units on a scale | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| Baseline | 17.1 ± 16.98 | 9.0 ± 12.56 | 9.0 ± 14.39 | 12.5 ± 11.69 | 6.8 ± 11.40 |
| Change at Week 5 | -5.6 ± 11.37 | 2.3 ± 10.05 | 4.7 ± 9.58 | -5.4 ± 12.28 | 0.5 ± 11.13 |
| Change at Week 10 | -3.3 ± 12.16 | -1.8 ± 7.98 | -6.5 ± 9.63 | -5.8 ± 13.50 | 1.0 ± 10.62 |
| Change at Week 15 | -11.5 ± 16.29 | 3.0 ± 10.30 | -3.3 ± 5.77 | -17.0 ± 11.34 | 0.4 ± 5.91 |
The PWC-20 is a physician completed, 20 item reliable and sensitive instrument for the assessment of discontinuation symptoms. The PWC-20 was collected after the completion of study treatment and also at the first visit of follow-up. The total PWC-20 score was the sum of 20 item scores and ranged from 0 to 60. If more than 5 items were missing, the total PWC-20 score was missing; otherwise, the total PWC-20 score was imputed as follows: sum of the non-missing items \* (total number of items) / (number of items non-missing). The higher score indicated more frequent/severe symptoms.
| units on a scale | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| Day 105 Early Termination (ET) | 3.5 ± 3.73 | 5.6 ± 5.68 | 5.8 ± 6.65 | 8.2 ± 8.78 | 7.1 ± 6.06 |
| Day 119 Follow-up (FU) | 3.3 ± 3.08 | 6.0 ± NA | — | 7.7 ± 4.16 | 5.8 ± 5.45 |
| Change From Day 105 ET to Day 119 FU | -0.6 ± 3.08 | -11.0 ± NA | — | -1.7 ± 4.73 | -0.4 ± 4.79 |
An AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event did not need necessarily to have a causal relationship with the treatment or usage. An SAE was any untoward medical occurrence at any dose that: * Resulted in death; * Was life threatening (immediate risk of death); * Required inpatient hospitalization or prolongation of existing hospitalization; * Resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); * Resulted in congenital anomaly/birth defect.
| Participants | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| AEs | 20 | 7 | 11 | 10 | 37 |
| SAEs | 1 | 1 | 0 | 0 | 2 |
| Discontinuation due to AEs | 3 | 1 | 3 | 2 | 9 |
| Death | 1 | 0 | 0 | 0 | 1 |
Collected over Day 1 to follow-up (Week 19 visit). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 1/23 (4.3%) | 1/23 (4.3%) | 15/23 (65.2%) |
| PF-06649751 1 mg QD | 0/13 (0%) | 1/13 (7.7%) | 7/13 (53.8%) |
| PF-06649751 3 mg QD | 0/15 (0%) | 0/15 (0%) | 11/15 (73.3%) |
| PF-06649751 7 mg QD | 0/13 (0%) | 0/13 (0%) | 10/13 (76.9%) |
| PF-06649751 15 mg QD | 1/44 (2.3%) | 2/44 (4.5%) | 31/44 (70.5%) |
| Event | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| NephrolithiasisRenal and urinary disorders | 0/23 | 1/13 | 0/15 | 0/13 | 0/44 |
| UreterolithiasisRenal and urinary disorders | 0/23 | 1/13 | 0/15 | 0/13 | 0/44 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/23 | 0/13 | 0/15 | 0/13 | 0/44 |
| Neck painMusculoskeletal and connective tissue disorders | 0/23 | 0/13 | 0/15 | 0/13 | 1/44 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/23 | 0/13 | 0/15 | 0/13 | 1/44 |
| Dermatitis allergicSkin and subcutaneous tissue disorders | 0/23 | 0/13 | 0/15 | 0/13 | 1/44 |
| Abdominal painGastrointestinal disorders | 0/23 | 0/13 | 0/15 | 0/13 | 1/44 |
| Allergic oedemaImmune system disorders | 0/23 | 0/13 | 0/15 | 0/13 | 1/44 |
| Event | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/23 | 2/13 | 2/15 | 1/13 | 11/44 |
| HeadacheNervous system disorders | 0/23 | 2/13 | 1/15 | 3/13 | 11/44 |
| DyskinesiaNervous system disorders | 2/23 | 1/13 | 1/15 | 3/13 | 7/44 |
| FatigueGeneral disorders | 3/23 | 1/13 | 2/15 | 2/13 | 1/44 |
| ContusionInjury, poisoning and procedural complications | 0/23 | 1/13 | 0/15 | 2/13 | 0/44 |
| FallInjury, poisoning and procedural complications | 2/23 | 2/13 | 1/15 | 2/13 | 2/44 |
| DizzinessNervous system disorders | 0/23 | 0/13 | 1/15 | 2/13 | 4/44 |
| HypotensionVascular disorders | 0/23 | 0/13 | 2/15 | 0/13 | 0/44 |
| NasopharyngitisInfections and infestations | 3/23 | 0/13 | 0/15 | 0/13 | 0/44 |
| InsomniaPsychiatric disorders | 3/23 | 1/13 | 0/15 | 1/13 | 2/44 |
| Age, Continuous(years) | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD | Total |
|---|---|---|---|---|---|---|
| Mean | 66.04 ± 8.79 | 66.92 ± 8.79 | 63.80 ± 7.76 | 67.77 ± 9.36 | 63.41 ± 8.47 | 64.97 ± 8.60 |
| Sex: Female, Male(Participants) | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD | Total |
|---|---|---|---|---|---|---|
| Female | 6 | 6 | 6 | 4 | 18 | 40 |
| Male | 17 | 7 | 9 | 9 | 26 | 68 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 1 | 1 | 3 | 11 |
| Not Hispanic or Latino | 20 | 10 | 13 | 12 | 40 | 95 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Placebo | PF-06649751 1 mg QD | PF-06649751 3 mg QD | PF-06649751 7 mg QD | PF-06649751 15 mg QD | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 1 | 0 | 2 | 1 | 6 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 0 | 2 | 1 | 6 |
| White | 20 | 12 | 12 | 9 | 36 | 89 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Mar 2016 to primary completion in Nov 2017, 20 months.
Results were first posted in Dec 2018, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tavapadon